The structured Diagnostic Interview for Sleep Patterns and Disorders: rationale and initial evaluation

Merikangas, Kathleen R.; J., Zhang,; Emsellem, Hélène A.; Swanson, Sonja A.; Vgontzas, Angeliki; Belouad, F.; Blank, Madeleine; Chen, W.; Einen, Mali; He, Jianmei; Heaton, Lisa J.; Nakamura, Erin F.; Rooholamini, Sahar N.; Mignot, Emmanuel

doi:10.1016/j.sleep.2013.10.011

Cited by 47 publications

(56 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The best cutoff for total score is >18, with a sensitivity of 82.2% and specificity of 86.9% . A structured interview based on the Diagnostic Interview for Sleep Patterns and Disorders (DISP) further confirmed the history of RBD symptoms …”

Section: Methodsmentioning

confidence: 87%

A case–control–family study of idiopathic rapid eye movement sleep behavior disorder

Liu

Zhang

Lam

et al. 2019

Annals of Neurology

View full text Add to dashboard Cite

Objective: To determine the familial aggregation of idiopathic rapid eye movement sleep behavior disorder (iRBD), neurodegenerative diseases, and related biomarkers. Methods: A total of 404 and 387 first-degree relatives of 102 patients with iRBD and of 89 controls were recruited, respectively. Among them, 204 and 208 relatives of patients and controls underwent face-to-face clinical assessment, whereas 97 and 75 relatives underwent further video-polysomnographic assessment, respectively. Results: Compared with relatives of controls, relatives of patients demonstrated higher levels of RBD features, including chin tonic electromyography activity (mean = 1.5 AE 7.5 vs 0.3 AE 1.0, p = 0.04) and behavioral events (n [weighted %] = 12 [11.3] vs 2 [1.9], adjusted hazard ratio [aHR] = 7.69, 95% confidence interval [CI] = 1.54-33.33, p = 0.009) during rapid eye movement sleep, probable diagnosis (n [%] = 57 [14.9] vs 20 [4.9], aHR = 3.45, 95% CI = 1.96-6.25, p < 0.001), and definite diagnosis (n [weighted %] = 10 [8.4] vs 2 [1.4], aHR = 5.56, 95% CI = 1.16-25.00, p = 0.03). They also had higher risks of Parkinson disease (3.1% vs 0.5%, aHR = 5.88, 95% CI = 1.37-25.00, p = 0.02), dementia (6.9% vs 2.6%, aHR = 2.44, 95% CI = 1.15-5.26, p = 0.02), constipation (8.3% vs 2.4%, adjusted odds ratio = 4.21, 95% CI = 1.34-13.17, p = 0.01), and motor dysfunction (Movement Disorders Society Unified Parkinson's Disease Rating Scale part III motor score, mean = 1.9 AE 3.2 vs 0.9 AE 2.3, p = 0.002). The unaffected relatives of patients demonstrated a higher likelihood ratio of prodromal Parkinson disease (median [interquartile range] = 0.27 [1.19] vs 0.22 [0.51], p = 0.03). Interpretation: iRBD is familially aggregated from isolated features to full-blown sleep disorder. Relatives of patients carry a higher risk of alpha-synucleinopathy in terms of neurodegenerative diseases and prodromal markers, suggesting a familial aggregation and staging pathology of alpha-synucleinopathy.

show abstract

Section: Methodsmentioning

confidence: 87%

A case–control–family study of idiopathic rapid eye movement sleep behavior disorder

Liu

Zhang

Lam

et al. 2019

Annals of Neurology

View full text Add to dashboard Cite

show abstract

“…Indeed, structured interviews for sleep disorders present good agreement with PSG and MSLT, having an accuracy of 80% for narcolepsy with cataplexy. 42 Patients with narcolepsy often experience more difficulties at their workplace than at home, especially because of their incapacity to remain awake during daytime. 24 Consequently, these individuals show lower employment rates and income levels than healthy patients.…”

Section: Discussionmentioning

confidence: 99%

Frequencies and Associations of Narcolepsy-Related Symptoms: A Cross-Sectional Study

Kim

Coelho

Hirotsu

et al. 2015

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

Objectives: Narcolepsy is a disabling disease with a delayed diagnosis. At least 3 years before the disorder identifi cation, several comorbidities can be observed in patients with narcolepsy. The early recognition of narcolepsy symptoms may improve long-term prognosis of the patients. Thus, we aimed to investigate the prevalence of the symptoms associated with narcolepsy and its social and psychological association in a sample of Sao Paulo city inhabitants. Methods: We performed a cross-sectional evaluation with 1,008 individuals from the Sao Paulo Epidemiologic Sleep Study (EPISONO). Excessive daytime sleepiness (EDS) was assessed by the Epworth Sleepiness Scale. Volunteers were also asked about the occurrence of cataplectic-like, hypnagogic or hypnopompic hallucinations, and sleep paralysis symptoms. The participants underwent a full-night polysomnography and completed questionnaires about psychological, demographic, and quality of life parameters. Results: We observed a prevalence of 39.2% of EDS, 15.0% of cataplectic-like symptom, 9.2% of hypnagogic or hypnopompic hallucinations, and 14.9% of sleep paralysis in Sao Paulo city inhabitants. A frequency of 6.9% was observed when EDS and cataplectic-like symptoms were grouped. The other associations were EDS + hallucinations (4.7%) and EDS + sleep paralysis (7.5%). Symptomatic participants were predominantly women and younger compared with patients without any narcolepsy symptom (n = 451). Narcolepsy symptomatology was also associated with a poor quality of life and symptoms of depression, anxiety, and fatigue. Conclusions: Narcolepsy-related symptoms are associated with poor quality of life and worse psychological parameters. A lthough narcolepsy may be considered a rare neurological condition, the repercussions of this disorder are substantial. Narcolepsy induces a 1.5-fold increase in the mortality rate compared with healthy individuals.1 As a consequence, narcoleptic patients have approximately 2-fold increased rates of hospital or other medical services admissions.2 Narcolepsy is often associated with a tetrad of symptoms, including, excessive daytime sleepiness (EDS), hypnagogic or hypnopompic hallucinations, sleep paralysis, and cataplexy. EDS is the most frequent symptom observed in narcoleptic patients. 3 In the natural history of EDS, several cardiometabolic and psychiatric conditions are associated with the incidence and persistence of EDS. 4 Patients with narcolepsy experience the symptoms over a long period until receiving the defi nitive diagnosis, ranging between 10 and 15 years. 5,6 A possible factor associated with this delay could be the failure to recognize the characteristic clinical features.7 Indeed, Jennum et al. demonstrated that narcoleptic patients present a wide range of comorbidities at least 3 years before the narcolepsy diagnosis, including a higher frequency of neurological diseases and other sleep disorders. 8 The recognition of the symptoms associated with narcolepsy seems to be an important approach for a better long-term progn...

show abstract

“…If the presentation is atypical, severe, or refractory to treatment, or if another disorder such as obstructive sleep apnea (OSA) is suspected, then PSG can be considered. In the case of OSA, the clinical predictors are neither sensitive nor specific, whether one considers tools such as the Epworth Sleepiness Scale (5) or the STOP-Bang survey (6), structured interviews (7), or even the clinical impression of experienced clinicians (8). Epidemiological studies suggest that the majority of individuals with OSA remain undiagnosed (9).…”

Section: Introductionmentioning

confidence: 99%

Sleep apnea in patients reporting insomnia or restless legs symptoms

2015

View full text Add to dashboard Cite

show abstract

The structured Diagnostic Interview for Sleep Patterns and Disorders: rationale and initial evaluation

Cited by 47 publications

References 49 publications

A case–control–family study of idiopathic rapid eye movement sleep behavior disorder

A case–control–family study of idiopathic rapid eye movement sleep behavior disorder

Frequencies and Associations of Narcolepsy-Related Symptoms: A Cross-Sectional Study

Sleep apnea in patients reporting insomnia or restless legs symptoms

Contact Info

Product

Resources

About